«The Vaccines Oral poliovirus vaccine (OPV) Globally many manufacturers produce the trivalent OPV using Sabin vaccine seeds provided by the World ...»
CDC (1996). Centers for Diseases Control and Prevention. Update: Vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices. MMWR: Morbidity and Mortality Weekly Report, 45(RR-12):1–35.
Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses--worldwide, July 2009-March
2011.MMWR Morb Mortal Wkly Rep. 2011 Jul 1;60(25):846-50.
Dittmann S (1992). Immunological preparations. MNG Dukes, ed. Meyer’s side effect of drugs, 12th Ed. Elsevier Science Publishers, 1992:791–840.
Esteves K (1988). Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bulletin of the World Health Organization, 66:739–46.
Galazka AM, Lauer BA, Henderson RH, Keja J (1984). Indications and contraindications for vaccines used in the Expanded Programme on Immunization. Bulletin of the World Health Organization, 62:357–66.
Global polio eradication initiative. Circulating VDPV data accessed on 10 December 2012 http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx.
Joce R, Wood D, Brown D, Begg NT (1992). Paralytic poliomyelitis in England and Wales, 1985–1991. British Medical Journal, 305:79–82.
Kelly H. Evidence for a causal association between oral polio vaccine and transverse myelitis: A case history and review of the Literature J Paediatr Child Health. 2006 Apr;42(4):155-9.
Kinnunen E, Farkkila M, Hovi T, et al. (1989). Incidence of Guillain–Barré syndrome during a nationwide oral poliovirus vaccine campaign. Neurology, 39:1036–6.
Kinnunen E, Junttila O, Haukka J, et al. (1998). Nationwide oral poliovirus vaccination campaign and the incidence of Guillain–Barré syndrome. American Journal of Epidemiology, 147: 69–73.
Manish Patel, A. Duncan Steele, Umesh D. Parashar (2011) Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines_Vaccine 30S (2012) A30– A35.
Maass G, Ouast U (1987). Acute spinal paralysis after the administration of oral poliomyelitis vaccine in the Federal Republic of Germany (1963–1984). The International Association of Biological Standardization, 15:185–191.
Murdin A, Barreto A, Vidor E (1996). Inactivated Polio Vaccine: past and present experience. Vaccine, 14:735–46.
Novello F, Lombardi F, Amato C, Santoro R, Fiore I, Grandolfo ME, Pasquini P (1987). Paralytic poliomyelitis in Italy, 1981–1985.
European Journal of Epidemiology I, 3:54–60.
Olen M. Kew, RolandW. Sutter,Esther M. de Gourville, Walter R. Dowdle,and Mark A. Pallansch Vaccine-Derived Polioviruses and the Endgame Strategy for Global Polio Eradication∗ Annu. Rev. Microbiol. 2005. 59:587–635.
Plotkin SA, Murdin A, Vidor E (1999). Inactivated Polio Vaccines. In Plotkin S, Orenstein W, eds. Vaccines. Philadelphia, PA, WB Saunders Company, 1999:345–363.
Rantala H, Cherry JD, Shields WD, et al. (1994). Epidemiology of Guillain–Barré syndrome in children: relationship of oral polio vaccine administration to occurrence. Journal of Pediatrics, 124:220–3.
Roure C, Rebiere I, Aymard M, Dubrou S (1991). Surveillance de la poliomyélite en France. Bulletin Epidemiologique Hebdomadaire 15: 59–61.
Stratton KR, Howe CJ, Johnston RB, Jr., eds. (1994). Adverse events associated with childhood vaccines. Evidence bearing on causality. Washington, DC, National Academy Press.
Strebel PM, Sutter RW, Cochi SL, et al. (1991). Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clinical Infectious Diseases, 14:568–79.
Sutter RW, Cochi SL, Melnick JL (1999). Live attenuated Poliovirus Vaccines in Plotkin SA, Orenstein WA, eds. Vaccines.
Philadelphia, PA, WB Saunders Company, 1999:364–408.
Sutter RW, Patriaca PA, Suleman AJM, Brogan S, Cochi SL, El-Bualy MS (1992). Attributable risk of DTP injection in provoking paralytic poliomyelitis during a large outbreak in Oman. Journal of Infectious Diseases, 165, 444–449.
Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RW, Cochi SL (1995). Intramuscular injections within 30 days of immunization
with oral poliovirus vaccine – a risk factor for vaccine-associated paralytic poliomyelitis. New England Journal of Medicine, 332:
Uhari M, Rantala H, Niemelä M (1989). Cluster of childhood Guillain–Barré cases after an oral poliovaccine campaign. Lancet, 2:440–1.
Varughese P, Caner A, Acres S, Furesz J (1989). Eradication of indigenous poliomyelitis in Canada: impact of immunization strategy. Canadian Public Health Journal, 80:363–8.
Vidor E, Caudrelier P, Plotkin S (1994). The place of DPT/eIPV vaccine in routine paediatric vaccination. Reviews in Medical Virology, 4:261–277.
Yeung WL et al. (1997). An infant with encephalitis. Lancet, 350:1594.
WER. Introduction of inactivated poliovirus into oral poliovirus using country. 2003: 28: 241-252.
WHO Global Eradication of Poliomyelitis. Report of the second meeting of the Global Technical Consultative Group.
WHO/EPI/GEN/98.04 This information sheet has been developed in close collaboration with the Global Advisory Committee on Vaccine Safety (GACVS). GACVS experts are independent and have declared no interests related to the expertise displayed in this product. Information displayed has been developed using primary sources such (Plotkin et al 2008, Institute of Medicine of the National Academies 2011) and from data derived from a literature search on Pubmed in 2008 using key words “vaccine antigen”, “Safety” and “adverse events”. An independent expert provided a first draft which was reviewed by nominated experts and the GACVS. Data of different vaccines that may be found in this product should only be compared if there is indication that a comparative randomised controlled trial has been undertaken. The information
sheets will be updated as new information may become available at the following web link: